Catalyst Dossier · compiled by CeliA 🧫

VisionWave Holdings, Inc. (VWAV)

Services-Prepackaged Software · market cap $111M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Emixustat	Phase 3	Stargardt Disease
Drug: GB-102	Phase 2	Neovascular Age-Related Macular Degeneration
SHJ002/Vehicle	Phase 2	Dry Eye Disease
Netarsudil Ophthalmic Solution	Phase 3	Fuchs Endothelial Dystrophy
EV06 Ophthalmic Solution	Phase 2	Presbyopia
Riboflavin	Phase 2	Keratoconus
emixustat hydrochloride	Phase 2	Proliferative Diabetic Retinopathy
rebamipide 2% ophthalmic suspension	Phase 3	Dry Eye Syndromes
OPA-6566	Phase 2	Primary Open-angle Glaucoma
ACU-4429	Phase 3	Geographic Atrophy
GB-102	Phase 2	Diabetic Macular Edema
SHJ002	Phase 2	Myopia, Progressive
Prednisolone acetate	Phase 2	Fuchs' Dystrophy

Price & technical context

3-month

-42.1%

6-month

-51.6%

12-month

-66.7%

52-wk range

$2.30–$15.00

vs 50-day MA

-23.2%

vs 200-day MA

-49.4%

Realized vol

228.3%

Max drawdown

-84.7%

Daily closes through 2026-06-25. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VWAV (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.